25th Apr 2018 13:41
LONDON (Alliance News) - Biotechnology company ValiRx PLC said Wednesday its VAL201 compound has been granted a patent in the EU.
This, it said, follows a US patent which was granted for VAL201, a proposed prostate cancer treatment currently in clinical trials, in March.
ValiRx said the patent grant was a "major" milestone for the company, with the treatment now having patent cover across much of the globe and in all major markets.
Shares were up 2.1% on Wednesday at 3.19 pence each.
Related Shares:
ValiRx